ArticleCureus2025
A Case of Persistent Bilateral Irvine-Gass Syndrome Following Uneventful Cataract Surgery in a Healthy Individual.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudophakic cystoid macular edema (PCME), also known as Irvine-Gass Syndrome, is one of the most common causes of postoperative visual impairment, which is usually self-limiting in nature. We report a case of persistent bilateral Irvine-Gass Syndrome (IGS) up to 11 months in a healthy individual despite an uneventful cataract surgery. A 58-year-old e-hailing male driver without any underlying systemic comorbidities complained of cloudy vision six weeks after uneventful bilateral cataract surgery. His best corrected visual acuity (BCVA) measured with the Early Treatment Diabetic Retinopathy Study (ETDRS) chart was 6/15 OD and 6/18 OS, which were initially thought to be attributed to bilateral early-onset posterior capsule opacity. At six months postoperatively, he underwent neodymium:yttrium-aluminum-garnet (Nd:YAG) posterior capsulotomy for both eyes. BCVA slightly improved to 6/12 OU, but optical coherence tomography (OCT) of both maculae showed cystoid macular edema. Initial treatment with topical nepafenac 0.1% three times daily was prescribed for three months, but Irvine-Gass Syndrome persisted; hence, bilateral orbital floor triamcinolone (OFTA) of 40 mg/1 ml injection was given. Anti-vascular endothelial growth factor (VEGF) was not considered in this case due to cost factors. Post orbital floor triamcinolone injection, there was persistent intraretinal cystic fluid. Unfortunately, there was no gain in visual acuity due to residual cystoid macular edema. Treatment was further escalated to sustained-release intravitreal dexamethasone implant 0.7 mg for both eyes. Following the dexamethasone implant, the bilateral macular edema resolved and was maintained throughout 120 days. This case illustrates the stepwise treatment approach in this patient without the presence of a definitive management guideline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.